수의용 단일클론항체 시장 분석 및 예측 : 유형, 제품 유형, 기술, 용도, 프로세스, 도입 상황, 최종 사용자, 기능, 솔루션, 단계(-2035년)

The global Monoclonal Antibodies In Veterinary Health Market is projected to grow from $1.3 billion in 2025 to $5.1 billion by 2035, at a compound annual growth rate (CAGR) of 13.1%. The Monoclonal Antibodies In Veterinary Health Market is characterized by a moderately consolidated structure, with the top segments being therapeutic antibodies, accounting for approximately 45% of the market share, followed by diagnostic antibodies at 30%, and prophylactic antibodies at 25%. Key applications include treatment of infectious diseases, cancer, and autoimmune disorders in animals. The market is driven by the increasing adoption of monoclonal antibodies for companion animals and livestock, with volume insights indicating a growing number of veterinary clinics and hospitals incorporating these products into their treatment protocols.

The monoclonal antibodies in veterinary health market is primarily segmented by type, with therapeutic antibodies leading the segment due to their effectiveness in treating chronic diseases in animals. Diagnostic antibodies also play a crucial role, particularly in early disease detection and management. The demand is driven by the increasing prevalence of zoonotic diseases and the need for advanced veterinary care. Notably, the development of novel antibody therapies is a significant growth trend, enhancing treatment outcomes and expanding the market scope.

In terms of technology, the hybridoma technology segment dominates due to its established efficacy in producing monoclonal antibodies. Recombinant DNA technology is gaining traction, offering enhanced specificity and reduced production costs. The demand for these technologies is fueled by the need for precise and efficient antibody production methods, particularly in developing vaccines and therapeutic agents. The continuous advancements in genetic engineering and biotechnology are propelling this segment's growth, promising more innovative solutions in veterinary health.

Geographical Overview

North America dominates the monoclonal antibodies in veterinary health market due to its strong animal healthcare ecosystem and high adoption of advanced biologics. The region benefits from widespread pet ownership and a strong trend of pet humanization, which drives increased spending on innovative treatments such as monoclonal antibody therapies. Well-established veterinary infrastructure, availability of specialized hospitals, and strong presence of leading animal health companies further support market growth. In addition, continuous research and development activities and increasing use of targeted therapies for chronic animal diseases significantly contribute to the region's leading position.

Asia Pacific is the fastest-growing region in the monoclonal antibodies in veterinary health market, driven by expanding animal healthcare awareness and rising pet adoption. Rapid economic development, increasing disposable incomes, and growing demand for advanced veterinary treatments are accelerating market expansion. Countries such as India and China are key growth hubs due to large animal populations and improving veterinary infrastructure. Additionally, increasing investments in research, rising availability of biologics, and supportive government initiatives aimed at strengthening animal health services are positioning the region as a major growth engine.

Key Trends and Drivers

Increasing Pet Ownership and Rising Focus on Animal Health:

The growth of the veterinary health market is strongly driven by increasing pet ownership and rising awareness about animal health and welfare. Pets are increasingly considered family members, leading to higher spending on preventive care, diagnostics, vaccinations, and treatment services. In addition, rising prevalence of chronic diseases, infections, and lifestyle-related conditions in both companion and livestock animals is boosting demand for advanced veterinary care. The expansion of veterinary services, improved access to clinics, and growing adoption of insurance coverage for pets are further accelerating market growth globally.

Expansion of Preventive Care, Digital Veterinary Services, and Emerging Markets:

A major opportunity in the veterinary health market lies in the expansion of preventive healthcare services and digital veterinary platforms. Increasing adoption of tele-veterinary consultations, AI-based diagnostics, and connected health monitoring systems is improving accessibility and efficiency of care delivery. Emerging markets also present strong growth potential due to rising disposable incomes, improving veterinary infrastructure, and growing awareness of animal health. In addition, investments in advanced diagnostics, personalized treatments, and biologics are creating new avenues for innovation. These factors are collectively enabling broader service reach and strengthening long-term market expansion.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Application
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Deployment
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Functionality
• 2.9 Key Market Highlights by Solutions
• 2.10 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Murine
  • 4.1.2 Chimeric
  • 4.1.3 Humanized
  • 4.1.4 Fully Human
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Antibodies
  • 4.2.2 Diagnostic Antibodies
  • 4.2.3 Others
• 4.3 Market Size & Forecast by Application (2020-2035)
  • 4.3.1 Infectious Diseases
  • 4.3.2 Cancer
  • 4.3.3 Autoimmune Disorders
  • 4.3.4 Inflammatory Diseases
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Hybridoma Technology
  • 4.4.2 Phage Display Technology
  • 4.4.3 Transgenic Mouse Technology
  • 4.4.4 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Veterinary Clinics
  • 4.5.2 Research Institutes
  • 4.5.3 Pharmaceutical Companies
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Deployment (2020-2035)
  • 4.6.1 In-house
  • 4.6.2 Outsourced
  • 4.6.3 Others
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Purification
  • 4.7.2 Characterization
  • 4.7.3 Production
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Functionality (2020-2035)
  • 4.8.1 Neutralizing Antibodies
  • 4.8.2 Binding Antibodies
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Therapeutic Solutions
  • 4.9.2 Diagnostic Solutions
  • 4.9.3 Others
• 4.10 Market Size & Forecast by Stage (2020-2035)
  • 4.10.1 Discovery
  • 4.10.2 Preclinical
  • 4.10.3 Clinical
  • 4.10.4 Commercial
  • 4.10.5 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Application
    • 5.2.1.4 Technology
    • 5.2.1.5 End User
    • 5.2.1.6 Deployment
    • 5.2.1.7 Process
    • 5.2.1.8 Functionality
    • 5.2.1.9 Solutions
    • 5.2.1.10 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Application
    • 5.2.2.4 Technology
    • 5.2.2.5 End User
    • 5.2.2.6 Deployment
    • 5.2.2.7 Process
    • 5.2.2.8 Functionality
    • 5.2.2.9 Solutions
    • 5.2.2.10 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Application
    • 5.2.3.4 Technology
    • 5.2.3.5 End User
    • 5.2.3.6 Deployment
    • 5.2.3.7 Process
    • 5.2.3.8 Functionality
    • 5.2.3.9 Solutions
    • 5.2.3.10 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Application
    • 5.3.1.4 Technology
    • 5.3.1.5 End User
    • 5.3.1.6 Deployment
    • 5.3.1.7 Process
    • 5.3.1.8 Functionality
    • 5.3.1.9 Solutions
    • 5.3.1.10 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Application
    • 5.3.2.4 Technology
    • 5.3.2.5 End User
    • 5.3.2.6 Deployment
    • 5.3.2.7 Process
    • 5.3.2.8 Functionality
    • 5.3.2.9 Solutions
    • 5.3.2.10 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Application
    • 5.3.3.4 Technology
    • 5.3.3.5 End User
    • 5.3.3.6 Deployment
    • 5.3.3.7 Process
    • 5.3.3.8 Functionality
    • 5.3.3.9 Solutions
    • 5.3.3.10 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Application
    • 5.4.1.4 Technology
    • 5.4.1.5 End User
    • 5.4.1.6 Deployment
    • 5.4.1.7 Process
    • 5.4.1.8 Functionality
    • 5.4.1.9 Solutions
    • 5.4.1.10 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Application
    • 5.4.2.4 Technology
    • 5.4.2.5 End User
    • 5.4.2.6 Deployment
    • 5.4.2.7 Process
    • 5.4.2.8 Functionality
    • 5.4.2.9 Solutions
    • 5.4.2.10 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Application
    • 5.4.3.4 Technology
    • 5.4.3.5 End User
    • 5.4.3.6 Deployment
    • 5.4.3.7 Process
    • 5.4.3.8 Functionality
    • 5.4.3.9 Solutions
    • 5.4.3.10 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Application
    • 5.4.4.4 Technology
    • 5.4.4.5 End User
    • 5.4.4.6 Deployment
    • 5.4.4.7 Process
    • 5.4.4.8 Functionality
    • 5.4.4.9 Solutions
    • 5.4.4.10 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Application
    • 5.4.5.4 Technology
    • 5.4.5.5 End User
    • 5.4.5.6 Deployment
    • 5.4.5.7 Process
    • 5.4.5.8 Functionality
    • 5.4.5.9 Solutions
    • 5.4.5.10 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Application
    • 5.4.6.4 Technology
    • 5.4.6.5 End User
    • 5.4.6.6 Deployment
    • 5.4.6.7 Process
    • 5.4.6.8 Functionality
    • 5.4.6.9 Solutions
    • 5.4.6.10 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Application
    • 5.4.7.4 Technology
    • 5.4.7.5 End User
    • 5.4.7.6 Deployment
    • 5.4.7.7 Process
    • 5.4.7.8 Functionality
    • 5.4.7.9 Solutions
    • 5.4.7.10 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Application
    • 5.5.1.4 Technology
    • 5.5.1.5 End User
    • 5.5.1.6 Deployment
    • 5.5.1.7 Process
    • 5.5.1.8 Functionality
    • 5.5.1.9 Solutions
    • 5.5.1.10 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Application
    • 5.5.2.4 Technology
    • 5.5.2.5 End User
    • 5.5.2.6 Deployment
    • 5.5.2.7 Process
    • 5.5.2.8 Functionality
    • 5.5.2.9 Solutions
    • 5.5.2.10 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Application
    • 5.5.3.4 Technology
    • 5.5.3.5 End User
    • 5.5.3.6 Deployment
    • 5.5.3.7 Process
    • 5.5.3.8 Functionality
    • 5.5.3.9 Solutions
    • 5.5.3.10 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Application
    • 5.5.4.4 Technology
    • 5.5.4.5 End User
    • 5.5.4.6 Deployment
    • 5.5.4.7 Process
    • 5.5.4.8 Functionality
    • 5.5.4.9 Solutions
    • 5.5.4.10 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Application
    • 5.5.5.4 Technology
    • 5.5.5.5 End User
    • 5.5.5.6 Deployment
    • 5.5.5.7 Process
    • 5.5.5.8 Functionality
    • 5.5.5.9 Solutions
    • 5.5.5.10 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Application
    • 5.5.6.4 Technology
    • 5.5.6.5 End User
    • 5.5.6.6 Deployment
    • 5.5.6.7 Process
    • 5.5.6.8 Functionality
    • 5.5.6.9 Solutions
    • 5.5.6.10 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Application
    • 5.6.1.4 Technology
    • 5.6.1.5 End User
    • 5.6.1.6 Deployment
    • 5.6.1.7 Process
    • 5.6.1.8 Functionality
    • 5.6.1.9 Solutions
    • 5.6.1.10 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Application
    • 5.6.2.4 Technology
    • 5.6.2.5 End User
    • 5.6.2.6 Deployment
    • 5.6.2.7 Process
    • 5.6.2.8 Functionality
    • 5.6.2.9 Solutions
    • 5.6.2.10 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Application
    • 5.6.3.4 Technology
    • 5.6.3.5 End User
    • 5.6.3.6 Deployment
    • 5.6.3.7 Process
    • 5.6.3.8 Functionality
    • 5.6.3.9 Solutions
    • 5.6.3.10 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Application
    • 5.6.4.4 Technology
    • 5.6.4.5 End User
    • 5.6.4.6 Deployment
    • 5.6.4.7 Process
    • 5.6.4.8 Functionality
    • 5.6.4.9 Solutions
    • 5.6.4.10 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Application
    • 5.6.5.4 Technology
    • 5.6.5.5 End User
    • 5.6.5.6 Deployment
    • 5.6.5.7 Process
    • 5.6.5.8 Functionality
    • 5.6.5.9 Solutions
    • 5.6.5.10 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Zoetis
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Boehringer Ingelheim
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Elanco Animal Health
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Merck Animal Health
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Bayer Animal Health
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Virbac
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Ceva Sante Animale
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Vetoquinol
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Phibro Animal Health
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Dechra Pharmaceuticals
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Heska Corporation
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Aratana Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 ImmuCell Corporation
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Neogen Corporation
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 IDEXX Laboratories
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Kindred Biosciences
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Abaxis
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Zomedica
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 PetMed Express
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Patterson Companies
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us